Get the Stockscreener App
28.90
0.55%
-0.14
Arcutis Biotherapeutics Inc stock is traded at $28.90, with a volume of 1.21M.
It is down -0.55% in the last 24 hours and down -1.87% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$29.04
Open:
$28.94
24h Volume:
1.21M
Relative Volume:
0.53
Market Cap:
$3.54B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-7.3724
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-0.31%
1M Performance:
-1.87%
6M Performance:
+109.88%
1Y Performance:
+98.35%
1-Day Range:
$28.49
$29.88
1-Week Range:
$27.71
$29.88
52-Week Range:
$11.13
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
28.88 | 3.56B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.49 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.78 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.15 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.54 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.38 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates - ts2.tech
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4%Still a Buy? - MarketBeat
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Lowered by Zacks Research - MarketBeat
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Simplify Asset Management Inc. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Wall Street Zen to Buy - MarketBeat
Arcutis Biotherapeutics Earnings Notes - Trefis
Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
Why Arcutis Biotherapeutics Inc. stock remains resilientRate Cut & Weekly Watchlist of Top Performers - Улправда
Perpetual Ltd Increases Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics Inc. stock gain from strong economyJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance Australia
Is Arcutis Biotherapeutics Inc. stock attractive for growth ETFsJuly 2025 EndofMonth & Momentum Based Trading Ideas - DonanımHaber
Price Action: Why Arcutis Biotherapeutics Inc. stock remains resilientJuly 2025 Review & Low Risk Entry Point Tips - Улправда
Investor Mood: What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Selloffs & Weekly Setup with ROI Potential - Улправда
What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Spike Watch & Detailed Earnings Play Alerts - Улправда
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Will Arcutis Biotherapeutics Inc. stock beat EPS estimatesMarket Movers & Low Drawdown Investment Ideas - Улправда
Squarepoint Ops LLC Has $2.35 Million Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 11,500 Shares of Stock - MarketBeat
Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest - Sahm
Arcutis Biotherapeutics Executive Sells Shares - TradingView — Track All Markets
Arcutis Biotherapeutics Insider Sold Shares Worth $332,851, According to a Recent SEC Filing - marketscreener.com
VP Burnett Sells 11,500 ($332.9K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView — Track All Markets
Arcutis (ARQT) CMO exercises options, sells 11,500 shares in plan trade - Stock Titan
This Biotech Stock Could Cure Your Portfolio's Pain - Finviz
Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals - Yahoo Finance
Arcutis Biotherapeutics, Inc. $ARQT Holdings Boosted by Frazier Life Sciences Management L.P. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Gilder Gagnon Howe & Co. LLC Purchases 59,712 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Eczema awareness campaign launched by actress Tori Spelling and Dr. Adam Friedman - KOKH
ARQT (Arcutis Biotherapeutics) OCF Margin % : -1.77% (As of Sep. 2025) - GuruFocus
Tori Spelling Teams Up with Arcutis to Share Her Family’s Eczema Journey - WKEF
Norges Bank Takes $2.45 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? - sharewise.com
Stempoint Capital LP Sells 334,401 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.7%What's Next? - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - BioSpace
Arcutis Biotherapeutics Appoints Amit Munshi as New Director - TipRanks
Amit Munshi joins Arcutis board as founder Chaudhuri retires - Investing.com
Arcutis Biotherapeutics Announces Board Changes - TradingView — Track All Markets
Amit Munshi joins Arcutis board as founder Chaudhuri retires By Investing.com - Investing.com India
Arcutis strengthens board of directors with new appointment of Amit Munshi - marketscreener.com
Arcutis Biotherapeutics | 12/8/25 - Channel 13 Las Vegas News KTNV
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcutis Biotherapeutics Inc Stock (ARQT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Burnett Patrick | See Remarks |
Dec 15 '25 |
Option Exercise |
3.64 |
11,500 |
41,860 |
109,807 |
| Burnett Patrick | See Remarks |
Dec 15 '25 |
Sale |
28.94 |
11,500 |
332,851 |
98,307 |
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):